IOVANCE BIOTHERAPEUTICS INC
NASDAQ: IOVA (Iovance Biotherapeutics, Inc.)
Last update: 11 hours ago13.62
-1.10 (-7.47%)
| Previous Close | 14.72 |
| Open | 14.65 |
| Volume | 12,194,239 |
| Avg. Volume (3M) | 16,884,459 |
| Market Cap | 6,169,470,976 |
| Price / Sales | 12.86 |
| Price / Book | 6.38 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -176.49% |
| Operating Margin (TTM) | -245.76% |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | 6,798.50% |
| Total Debt/Equity (MRQ) | 7.00% |
| Current Ratio (MRQ) | 4.18 |
| Operating Cash Flow (TTM) | -334.39 M |
| Levered Free Cash Flow (TTM) | -184.76 M |
| Return on Assets (TTM) | -27.14% |
| Return on Equity (TTM) | -51.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Iovance Biotherapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.50 |
Select this tab to load the latest available analysis.
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 81.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mhr Fund Management Llc | 30 Jun 2026 | 28,967,103 |
| Palo Alto Investors Lp | 30 Jun 2026 | 5,296,209 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |